Cargando…

Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report

INTRODUCTION: We describe a case of a large type III neuroendocrine tumor of the stomach. Management and current literature are reviewed. PRESENTATION OF CASE: A 37 year old female presented with upper gastrointestinal bleed and epigastric pain. Further workup demonstrated a large ulcerated gastric...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellorin, Omar, Shuchleib, Ariel, Halevi, Alexandra E., Aksenov, Sergei, Saldinger, Pierre F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917394/
https://www.ncbi.nlm.nih.gov/pubmed/27327559
http://dx.doi.org/10.1016/j.ijscr.2016.06.008
_version_ 1782438940928638976
author Bellorin, Omar
Shuchleib, Ariel
Halevi, Alexandra E.
Aksenov, Sergei
Saldinger, Pierre F.
author_facet Bellorin, Omar
Shuchleib, Ariel
Halevi, Alexandra E.
Aksenov, Sergei
Saldinger, Pierre F.
author_sort Bellorin, Omar
collection PubMed
description INTRODUCTION: We describe a case of a large type III neuroendocrine tumor of the stomach. Management and current literature are reviewed. PRESENTATION OF CASE: A 37 year old female presented with upper gastrointestinal bleed and epigastric pain. Further workup demonstrated a large ulcerated gastric mass near the GE junction. Computer tomography scan and endoscopic ultrasound showed a 10 cm mass with no evidence of distant disease. Fine needle aspiration pathology was consistent with a well differentiated neuroendocrine tumor (Ki67 index <2%), with elevated levels of chromogranin A and serotonin levels but normal gastrin. The patient underwent an uneventful total gastrectomy. Final pathology analysis reported a higher KI67 index (7.54%) and a final pathology of grade 2 type III, T3 N3, neuroendocrine tumor of the stomach. The chromogranin levels normalized and no recurrent disease has been detected in one year follow up. DISCUSSION: Gastric neuroendocrine tumors are extremely rare, accounting for 4% of all neuroendocrine tumors of the body and 1% of all neoplasms of the stomach. Based on histomorphologic characteristics and pathogenesis, gastric neuroendocrine tumors are classified into four types with differing prognosis and behavior. Current literature describes type 3 gastric neuroendocrine tumors as larger than 2 cm. However, there is no precedent in the literature for a tumor of this size. CONCLUSION: The incidence of gastric neuroendocrine tumors has been increasing during the last decade, underscoring the need to improve our understanding of their biology and behavior. When identified histologically, patient outcomes depend on appropriate determination of tumor biology and subsequent choice of treatment.
format Online
Article
Text
id pubmed-4917394
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-49173942016-06-29 Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report Bellorin, Omar Shuchleib, Ariel Halevi, Alexandra E. Aksenov, Sergei Saldinger, Pierre F. Int J Surg Case Rep Case Report INTRODUCTION: We describe a case of a large type III neuroendocrine tumor of the stomach. Management and current literature are reviewed. PRESENTATION OF CASE: A 37 year old female presented with upper gastrointestinal bleed and epigastric pain. Further workup demonstrated a large ulcerated gastric mass near the GE junction. Computer tomography scan and endoscopic ultrasound showed a 10 cm mass with no evidence of distant disease. Fine needle aspiration pathology was consistent with a well differentiated neuroendocrine tumor (Ki67 index <2%), with elevated levels of chromogranin A and serotonin levels but normal gastrin. The patient underwent an uneventful total gastrectomy. Final pathology analysis reported a higher KI67 index (7.54%) and a final pathology of grade 2 type III, T3 N3, neuroendocrine tumor of the stomach. The chromogranin levels normalized and no recurrent disease has been detected in one year follow up. DISCUSSION: Gastric neuroendocrine tumors are extremely rare, accounting for 4% of all neuroendocrine tumors of the body and 1% of all neoplasms of the stomach. Based on histomorphologic characteristics and pathogenesis, gastric neuroendocrine tumors are classified into four types with differing prognosis and behavior. Current literature describes type 3 gastric neuroendocrine tumors as larger than 2 cm. However, there is no precedent in the literature for a tumor of this size. CONCLUSION: The incidence of gastric neuroendocrine tumors has been increasing during the last decade, underscoring the need to improve our understanding of their biology and behavior. When identified histologically, patient outcomes depend on appropriate determination of tumor biology and subsequent choice of treatment. Elsevier 2016-06-16 /pmc/articles/PMC4917394/ /pubmed/27327559 http://dx.doi.org/10.1016/j.ijscr.2016.06.008 Text en © 2016 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Bellorin, Omar
Shuchleib, Ariel
Halevi, Alexandra E.
Aksenov, Sergei
Saldinger, Pierre F.
Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report
title Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report
title_full Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report
title_fullStr Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report
title_full_unstemmed Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report
title_short Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report
title_sort giant type iii well-differentiated neuroendocrine tumor of the stomach: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917394/
https://www.ncbi.nlm.nih.gov/pubmed/27327559
http://dx.doi.org/10.1016/j.ijscr.2016.06.008
work_keys_str_mv AT bellorinomar gianttypeiiiwelldifferentiatedneuroendocrinetumorofthestomachacasereport
AT shuchleibariel gianttypeiiiwelldifferentiatedneuroendocrinetumorofthestomachacasereport
AT halevialexandrae gianttypeiiiwelldifferentiatedneuroendocrinetumorofthestomachacasereport
AT aksenovsergei gianttypeiiiwelldifferentiatedneuroendocrinetumorofthestomachacasereport
AT saldingerpierref gianttypeiiiwelldifferentiatedneuroendocrinetumorofthestomachacasereport